<DOC>
	<DOC>NCT01990300</DOC>
	<brief_summary>The purpose of this study is to examine the safety and efficacy of long-term use of alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus determined as warranting combination therapy with alogliptin benzoate and pioglitazone hydrochloride</brief_summary>
	<brief_title>Alogliptin/Pioglitazone (Liovel) Liovel Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This is a special drug use surveillance on long-term use of alogliptin/pioglitazone combination tablets. This study is designed to investigate the safety and efficacy of long-term use of alogliptin/pioglitazone combination tablet in patients with type 2 diabetes mellitus in the routine clinical setting. Participants will be patients with type 2 diabetes mellitus. The planned sample size is 3000. The usual adult dosage is 1 tablet (containing alogliptin/pioglitazone at either 25 mg/15 mg or 25 mg/30 mg) taken orally once daily before or after breakfast.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Patients with type 2 diabetes mellitus Patients meeting any of the following criteria will be excluded: 1. Patients with current cardiac failure or a past history of cardiac failure 2. Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus 3. Patients with serious hepatic dysfunction 4. Patients with serious renal dysfunction 5. Patients with severe infection, pre or postoperative patients, or patients with serious traumatic injury 6. Patients with a history of hypersensitivity to any ingredients of Liovel 7. Pregnant or possibly pregnant women</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>